| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -34,770 | -25,500 | -30,090 | -26,960 | -20,610 |
| Net Income Growth | -36.35% | +15.25% | -11.61% | -30.81% | -15.59% |
Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company develops medicines in areas of significant unmet medical need in oncology principally in the United States. Its lead drug candidate is oral (Z)-endoxifen. Atossa Therapeutics Inc., formerly known as Atossa Genetics Inc., is based in Seattle, Washington.
Fiscal Year End Date: 12/31